Published in RNA on May 08, 2006
Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46
The promises and pitfalls of RNA-interference-based therapeutics. Nature (2009) 7.53
Determinants of targeting by endogenous and exogenous microRNAs and siRNAs. RNA (2007) 6.44
Structure of an argonaute silencing complex with a seed-containing guide DNA and target RNA duplex. Nature (2008) 5.78
Distance constraints between microRNA target sites dictate efficacy and cooperativity. Nucleic Acids Res (2007) 4.91
Predicting effective microRNA target sites in mammalian mRNAs. Elife (2015) 4.30
Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov (2010) 4.25
Expanding the microRNA targeting code: functional sites with centered pairing. Mol Cell (2010) 4.20
Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol (2009) 3.66
RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43
Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A (2007) 3.30
Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res (2008) 3.18
RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev (2007) 3.13
Off-target effects by siRNA can induce toxic phenotype. RNA (2006) 2.89
Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene (2008) 2.83
Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest (2007) 2.78
Systems biology in immunology: a computational modeling perspective. Annu Rev Immunol (2011) 2.15
Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol (2006) 1.97
TULP3 bridges the IFT-A complex and membrane phosphoinositides to promote trafficking of G protein-coupled receptors into primary cilia. Genes Dev (2010) 1.95
Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov (2013) 1.93
Experimental validation of the importance of seed complement frequency to siRNA specificity. RNA (2008) 1.92
Vigilance and validation: Keys to success in RNAi screening. ACS Chem Biol (2010) 1.85
A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res (2009) 1.84
Chemical modification: the key to clinical application of RNA interference? J Clin Invest (2007) 1.81
Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J Exp Med (2012) 1.76
Signatures of RNA binding proteins globally coupled to effective microRNA target sites. Genome Res (2010) 1.75
Silencing disease genes in the laboratory and the clinic. J Pathol (2011) 1.72
Strand-specific 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA (2007) 1.61
Progress toward in vivo use of siRNAs-II. Mol Ther (2011) 1.60
RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med (2009) 1.59
Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res (2007) 1.53
Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA (2007) 1.46
Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing. Proc Natl Acad Sci U S A (2009) 1.43
Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther (2013) 1.42
Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer. PLoS Genet (2008) 1.39
Thermodynamic stability and Watson-Crick base pairing in the seed duplex are major determinants of the efficiency of the siRNA-based off-target effect. Nucleic Acids Res (2008) 1.39
Modulating the expression of disease genes with RNA-based therapy. PLoS Genet (2007) 1.38
Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res (2008) 1.37
Multiparametric analysis of focal adhesion formation by RNAi-mediated gene knockdown. J Cell Biol (2009) 1.36
Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Deliv Rev (2010) 1.32
MicroRNA-like off-target transcript regulation by siRNAs is species specific. RNA (2009) 1.27
Increased siRNA duplex stability correlates with reduced off-target and elevated on-target effects. RNA (2011) 1.26
A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res (2010) 1.26
Localization of double-stranded small interfering RNA to cytoplasmic processing bodies is Ago2 dependent and results in up-regulation of GW182 and Argonaute-2. Mol Biol Cell (2008) 1.20
Activation of LDL receptor expression by small RNAs complementary to a noncoding transcript that overlaps the LDLR promoter. Chem Biol (2010) 1.20
Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects. Mol Ther (2009) 1.19
Knocking down disease: a progress report on siRNA therapeutics. Nat Rev Genet (2015) 1.19
Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther (2012) 1.18
Effect of base modifications on structure, thermodynamic stability, and gene silencing activity of short interfering RNA. RNA (2007) 1.16
Circ-ZNF609 Is a Circular RNA that Can Be Translated and Functions in Myogenesis. Mol Cell (2017) 1.15
Research progress on siRNA delivery with nonviral carriers. Int J Nanomedicine (2011) 1.13
Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5'-terminal phosphorylation both in vitro and in vivo. Nucleic Acids Res (2009) 1.10
Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference. Nucleic Acids Res (2015) 1.10
RNAi: a potential new class of therapeutic for human genetic disease. Hum Genet (2011) 1.10
The PIDDosome mediates delayed death of hippocampal CA1 neurons after transient global cerebral ischemia in rats. Proc Natl Acad Sci U S A (2008) 1.10
Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. Mol Ther (2011) 1.09
A human genome-wide screen for regulators of clathrin-coated vesicle formation reveals an unexpected role for the V-ATPase. Nat Cell Biol (2013) 1.09
Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers. ACS Nano (2012) 1.08
RNA major groove modifications improve siRNA stability and biological activity. Nucleic Acids Res (2008) 1.07
Knockdown of TNFR1 by the sense strand of an ICAM-1 siRNA: dissection of an off-target effect. Nucleic Acids Res (2007) 1.06
Identification of an inter-transcription factor regulatory network in human hepatoma cells by Matrix RNAi. Nucleic Acids Res (2009) 1.06
RNAi for treating hepatitis B viral infection. Pharm Res (2007) 1.05
Controlling activation of the RNA-dependent protein kinase by siRNAs using site-specific chemical modification. Nucleic Acids Res (2006) 1.04
2'-fluoro-4'-thioarabino-modified oligonucleotides: conformational switches linked to siRNA activity. Nucleic Acids Res (2007) 1.03
2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun (2014) 1.03
Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs. RNA (2009) 1.02
The Business of RNAi Therapeutics in 2012. Mol Ther Nucleic Acids (2012) 1.01
The ESCRT machinery is recruited by the viral BFRF1 protein to the nucleus-associated membrane for the maturation of Epstein-Barr Virus. PLoS Pathog (2012) 1.01
Limited agreement of independent RNAi screens for virus-required host genes owes more to false-negative than false-positive factors. PLoS Comput Biol (2013) 1.01
Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev (2015) 1.01
Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs. Nucleic Acids Res (2010) 1.01
siPools: highly complex but accurately defined siRNA pools eliminate off-target effects. Nucleic Acids Res (2014) 1.01
Non-stimulated, agonist-stimulated and store-operated Ca2+ influx in MDA-MB-468 breast cancer cells and the effect of EGF-induced EMT on calcium entry. PLoS One (2012) 1.00
Efficient and specific gene knockdown by small interfering RNAs produced in bacteria. Nat Biotechnol (2013) 1.00
Multiplexing siRNAs to compress RNAi-based screen size in human cells. Nucleic Acids Res (2007) 0.98
Chemical modification resolves the asymmetry of siRNA strand degradation in human blood serum. RNA (2007) 0.97
Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics. Hum Mol Genet (2009) 0.97
Off-target and a portion of target-specific siRNA mediated mRNA degradation is Ago2 'Slicer' independent and can be mediated by Ago1. Nucleic Acids Res (2009) 0.97
Primary ciliogenesis requires the distal appendage component Cep123. Biol Open (2013) 0.97
Effect of chemical modifications on modulation of gene expression by duplex antigene RNAs that are complementary to non-coding transcripts at gene promoters. Nucleic Acids Res (2010) 0.97
Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression. J Biol Chem (2008) 0.96
Single-stranded microRNA mimics. RNA (2012) 0.96
Cyclin G-associated kinase promotes microtubule outgrowth from chromosomes during spindle assembly. Chromosoma (2010) 0.96
Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering. Front Genet (2012) 0.95
siRNA off-target effects can be reduced at concentrations that match their individual potency. PLoS One (2011) 0.95
Inhibition of dengue virus entry and multiplication into monocytes using RNA interference. PLoS Negl Trop Dis (2011) 0.94
Maternally recruited DCP1A and DCP2 contribute to messenger RNA degradation during oocyte maturation and genome activation in mouse. Biol Reprod (2013) 0.94
Host gene targets for novel influenza therapies elucidated by high-throughput RNA interference screens. FASEB J (2012) 0.93
siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse. Nucleic Acids Res (2012) 0.93
Developing microRNA screening as a functional genomics tool for disease research. Front Physiol (2013) 0.92
Modified dsRNAs that are not processed by Dicer maintain potency and are incorporated into the RISC. Nucleic Acids Res (2010) 0.91
Oligonucleotide-based strategies to combat polyglutamine diseases. Nucleic Acids Res (2014) 0.90
Designing of highly effective complementary and mismatch siRNAs for silencing a gene. PLoS One (2011) 0.90
Trafficking of tachykinin neurokinin 3 receptor to nuclei of neurons in the paraventricular nucleus of the hypothalamus following osmotic challenge. Neuroscience (2008) 0.89
Distinct regulation of cytoplasmic calcium signals and cell death pathways by different plasma membrane calcium ATPase isoforms in MDA-MB-231 breast cancer cells. J Biol Chem (2012) 0.89
Dual-targeting siRNAs. RNA (2010) 0.89
Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma. World J Gastroenterol (2008) 0.88
Lack of correlation between predicted and actual off-target effects of short-interfering RNAs targeting the human papillomavirus type 16 E7 oncogene. Br J Cancer (2013) 0.88
Advances in Systemic siRNA Delivery. Drugs Future (2009) 0.87
Snap-to-it probes: chelate-constrained nucleobase oligomers with enhanced binding specificity. Nucleic Acids Res (2008) 0.87
Improved tools for biological sequence comparison. Proc Natl Acad Sci U S A (1988) 193.60
Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res (2003) 77.89
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature (2005) 48.95
Asymmetry in the assembly of the RNAi enzyme complex. Cell (2003) 22.18
Specificity of microRNA target selection in translational repression. Genes Dev (2004) 21.14
Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol (2003) 16.63
Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell (2005) 15.26
Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nat Biotechnol (2001) 14.57
Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J (2001) 12.88
ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell (2001) 10.20
Structural basis for 5'-end-specific recognition of guide RNA by the A. fulgidus Piwi protein. Nature (2005) 7.12
Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA (2006) 7.06
The crystal structure of the Argonaute2 PAZ domain reveals an RNA binding motif in RNAi effector complexes. Nat Struct Biol (2003) 6.90
Structural insights into mRNA recognition from a PIWI domain-siRNA guide complex. Nature (2005) 6.23
siRNA function in RNAi: a chemical modification analysis. RNA (2003) 4.93
Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res (2003) 3.85
Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem (1993) 3.70
Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res (2003) 3.39
Synthesis and hybridization studies on two complementary nona(2'-O-methyl)ribonucleotides. Nucleic Acids Res (1987) 3.24
siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res (2005) 3.21
Off-target effects by siRNA can induce toxic phenotype. RNA (2006) 2.89
RNA interference in mammalian cells by chemically-modified RNA. Biochemistry (2003) 2.62
Hybridization arrest of globin synthesis in rabbit reticulocyte lysates and cells by oligodeoxyribonucleoside methylphosphonates. Biochemistry (1985) 2.60
Characterization of fully 2'-modified oligoribonucleotide hetero- and homoduplex hybridization and nuclease sensitivity. Nucleic Acids Res (1995) 2.30
Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J Med Chem (2005) 2.05
Target accessibility dictates the potency of human RISC. Nat Struct Mol Biol (2005) 1.78
Oligodeoxynucleotides containing 2'-O-modified adenosine: synthesis and effects on stability of DNA:RNA duplexes. Biochemistry (1993) 1.71
Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity. RNA (2005) 1.38
Stabilizing effects of the RNA 2'-substituent: crystal structure of an oligodeoxynucleotide duplex containing 2'-O-methylated adenosines. Chem Biol (1994) 1.32
Oligothymidylate analogues having stereoregular, alternating methylphosphonate/phosphodiester backbones as primers for DNA polymerase. Biochemistry (1982) 1.13
The 1.19 A X-ray structure of 2'-O-Me(CGCGCG)(2) duplex shows dehydrated RNA with 2-methyl-2,4-pentanediol in the minor groove. Nucleic Acids Res (2001) 1.04
Solution structure of an RNA.2'-O-methylated RNA hybrid duplex containing an RNA.DNA hybrid segment at the center. Biochemistry (1997) 0.97
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature (2005) 48.95
Genetics of gene expression surveyed in maize, mouse and man. Nature (2003) 22.17
Mapping the genetic architecture of gene expression in human liver. PLoS Biol (2008) 19.44
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
Functional siRNAs and miRNAs exhibit strand bias. Cell (2003) 19.15
Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol (2003) 16.63
Rational siRNA design for RNA interference. Nat Biotechnol (2004) 14.16
A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 8.67
The genome of the cucumber, Cucumis sativus L. Nat Genet (2009) 8.19
Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature (2005) 7.24
Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA (2006) 7.06
3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods (2006) 6.96
Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol (2007) 6.43
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol (2005) 6.18
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol (2008) 5.21
Simple, quantitative primer-extension PCR assay for direct monitoring of microRNAs and short-interfering RNAs. RNA (2005) 5.20
MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol (2008) 4.76
Identification of the gene for vitamin K epoxide reductase. Nature (2004) 4.52
Analysis of clathrin-mediated endocytosis of epidermal growth factor receptor by RNA interference. J Biol Chem (2004) 4.32
Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov (2010) 4.25
Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant (2005) 4.05
Expression of 24,426 human alternative splicing events and predicted cis regulation in 48 tissues and cell lines. Nat Genet (2008) 3.78
miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med (2011) 3.78
Digital transcriptome profiling using selective hexamer priming for cDNA synthesis. Nat Methods (2009) 3.73
Identification of genes that regulate epithelial cell migration using an siRNA screening approach. Nat Cell Biol (2008) 3.72
Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A (2006) 3.70
Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol (2004) 3.67
A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc Natl Acad Sci U S A (2008) 3.33
Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet (2006) 3.23
MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle (2009) 3.07
Production of complex nucleic acid libraries using highly parallel in situ oligonucleotide synthesis. Nat Methods (2004) 3.01
Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc Natl Acad Sci U S A (2005) 2.90
Off-target effects by siRNA can induce toxic phenotype. RNA (2006) 2.89
A quantitative atlas of polyadenylation in five mammals. Genome Res (2012) 2.87
Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. Cancer Res (2008) 2.86
Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies. Nat Methods (2007) 2.83
Family influences on the risk of daily smoking initiation. J Adolesc Health (2005) 2.80
Global survey of genomic imprinting by transcriptome sequencing. Curr Biol (2008) 2.80
Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem (2009) 2.76
Case records of the Massachusetts General Hospital. Case 36-2014. An 18-year-old woman with fever, pharyngitis, and double vision. N Engl J Med (2014) 2.72
MicroRNAs and cell cycle regulation. Cell Cycle (2007) 2.62
Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol (2011) 2.52
The contributions of dsRNA structure to Dicer specificity and efficiency. RNA (2005) 2.48
Noise amidst the silence: off-target effects of siRNAs? Trends Genet (2004) 2.38
Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem (2006) 2.35
Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc Natl Acad Sci U S A (2002) 2.32
A comprehensive transcript index of the human genome generated using microarrays and computational approaches. Genome Biol (2004) 2.21
Induction of the interferon response by siRNA is cell type- and duplex length-dependent. RNA (2006) 2.17
Median absolute deviation to improve hit selection for genome-scale RNAi screens. J Biomol Screen (2008) 2.12
Fast cleavage kinetics of a natural hammerhead ribozyme. J Am Chem Soc (2004) 2.00
Folding of the natural hammerhead ribozyme is enhanced by interaction of auxiliary elements. RNA (2004) 1.99
Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol (2006) 1.97
Myc-regulated microRNAs attenuate embryonic stem cell differentiation. EMBO J (2009) 1.94
Prediction of yeast protein-protein interaction network: insights from the Gene Ontology and annotations. Nucleic Acids Res (2006) 1.93
Experimental validation of the importance of seed complement frequency to siRNA specificity. RNA (2008) 1.92